Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment

Atzori, Laura

First

Writing - Review & Editing

;Bonato, Filippo

Second

Writing - Original Draft Preparation

;Pilloni, Luca

Penultimate

Member of the Collaboration Group

;Rongioletti, Franco

Last

Supervision

2020-01-01

---

Abstract

Mental retardation is a potential limitation to self-administration of innovative biologic treatment, which is otherwise very effective for devastating chronic inflammatory conditions, such as hidradenitis suppurativa (HS). We report our successful experience with a 34-year-old woman, who was genetically affected by Warkany syndrome, which causes intellectual disability. This patient was unable to maintain long-term antibiotic regimen and was disappointed by the limited results in her 12 years' history of painful draining fistulae and abscesses; however, she enthusiastically adhered to adalimumab 40 mg/once weekly treatment. After 52 weeks, treatment compliance is excellent, the patient is satisfied with the HS improvements, and no adverse effects have been reported.